David Machnik

USPTO Granted Patents = 16 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 107(Granted Patents)

Location History:

Antony, FR (2012)
Paris, FR (1999 - 2022)

Company Filing History:

Lead Pharma Holding B.v.

where one patent can have more than one assignee

Years Active: 1999-2022

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11299456 - ROR gamma (RORγ) modulators (2022-04-12),

2. 10196350 - ROR gamma (RORγ) modulators (2019-02-05),

3. 10118895 - ROR gamma (RORγ) modulators (2018-11-06),

4. 8716273 - [object Object] (2014-05-06),

5. 8716272 - [object Object] (2014-05-06),

6. 8598166 - Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof (2013-12-03),

7. 8586573 - N-(Aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof (2013-11-19),

8. 8354425 - Azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof (2013-01-15),

9. 8338451 - [object Object] (2012-12-25),

10. 8288376 - [object Object] (2012-10-16),

11. 8153650 - N-(amino-heteroaryl)-1H-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy (2012-04-10),

12. 8143248 - Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use (2012-03-27),

13. 8088765 - Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof (2012-01-03),

14. 7786104 - N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof (2010-08-31),

15. 6221879 - 8-azabicyclo[3.2.1] octane-3-methanamine derivatives as ligands of D2 and D3 dopamine and 5HT1A and 5HT2 serotonin receptors (2001-04-24),

Title: David Machnik: Innovator in ROR Gamma Modulation

Introduction

David Machnik is a prominent inventor based in Paris, France. He holds a remarkable portfolio of 16 patents, showcasing his significant contribution to the field of innovation. His most recent work focuses on ROR gamma (RORγ) modulators, which have the potential to treat various RORγ-mediated diseases. This article will explore his latest patents, career highlights, and collaborations.

Latest Patents

David Machnik's latest patents revolve around compounds identified in formulas IA and IB. These compounds are designed as inhibitors of RORγ, making them instrumental in the treatment of diseases associated with this particular pathway. The innovative nature of his work underscores his commitment to advancing medical science through significant discoveries in modulation.

Career Highlights

Throughout his career, David has made impactful contributions while working with notable companies such as Sanofi and Sanofi-Aventis. His experience in these organizations has not only honed his skills but also shaped his vision as an inventor dedicated to improving healthcare.

Collaborations

During his journey, David Machnik has collaborated with esteemed colleagues, including Yannick Evanno and Laurent Dubois. Their teamwork reflects a shared commitment to scientific innovation and the advancement of their respective fields.

Conclusion

David Machnik's innovative spirit and persistent dedication to developing ROR gamma modulators has marked him as a noteworthy figure in the realm of inventors. With his extensive patent portfolio and collaborative endeavors, he continues to pave the way for future breakthroughs in medical treatment and beyond.

This text is generated by artificial intelligence and may not be accurate.